Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of knockdown of amphiregulin or SGK3 on global gene expression in letrozole resistant breast cancer cells

ABSTRACT: The effect of knockdown of amphiregulin or SGK3 on global gene expression in letrozole resistant breast cancer cells

PROVIDER: PRJNA625749 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11557547.fastq.gz	Fastqsanger.gz
	SRR11557548.fastq.gz	Fastqsanger.gz
	SRR11557549.fastq.gz	Fastqsanger.gz
	SRR11557550.fastq.gz	Fastqsanger.gz
	SRR11557551.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

The effect of knockdown of amphiregulin or SGK3 on global gene expression in letrozole resistant breast cancer cells

Project description:LET-R cells were reversely transfected with siRNA negative control, AREG siRNA or SGK3 siRNA for 48 h, and then harvested for RNA sequencing.

2020-04-23 | GSE148800 | GEO

Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

Project description:Biopsies were collected from post-menopausal women with ER+ HER2- breast cancer who were subsequently treated with either letrozole or letrozole plus bevacizumab.

2019-12-19 | GSE142308 | GEO

ER ChIP-seq of Androstenedione treated Letrozole Resistant Breast Cancer Cell line

Project description:Acquired resistance to aromatase inhibitor (AI) therapy is a major clinical problem in the treatment of breast cancer. The detailed mechanisms of how tumour cells develop this resistance remain unclear. Here estrogen receptor ChIPseq analysis identifies adaptations of the ER in response to prolonged letrozole treatment.

2016-03-21 | GSE54592 | GEO

RNA sequencing of ER+ breast tumor treated with letrozole

Project description:Transcriptome of ER+ breast tumors treated with letrozole were profiled by RNA-seq

2020-07-01 | GSE145325 | GEO

Effect of Amphiregulin on global gene expression in injured skeletal muscle in the presence or absence of CD4+Foxp3+ regulatory T cells (Tregs).

Project description:Global gene expression analysis of injured skeletal muscle showed that amphiregulin (Areg), a growth factor over-expressed by muscle Treg cells, enhances muscle regeneration both in the presence and in the absence of Tregs. Foxp3-DTR+ and Foxp3-DTR- mice were injured with cardiotoxin in TA muscle at day 0 and treated with diphtheria toxin every other day from day 0 until dissection. Amphiregulin or PBS were administered im on day 0 and ip every other day until dissection. TA muscle was flash-frozen and RNA was extracted using Trizol. RNA from whole tissue samples was amplified, labeled, and hybridized to Affymetrix Mouse Gene 1.0 ST Arrays.

2013-12-15 | E-GEOD-50097 | biostudies-arrayexpress

White adipose tissues: amphiregulin overexpression

Project description:Transcriptional profiling of transgenic mice specifically expressing amphiregulin in white adipose tissues. The objective of this study is to explore gene expression profiles of adipose tissues in response to amphiregulin overexpression.

2017-09-15 | GSE103875 | GEO

Effect of Amphiregulin on global gene expression in injured skeletal muscle in the presence or absence of CD4+Foxp3+ regulatory T cells (Tregs).

2013-12-15 | GSE50097 | GEO

Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

Project description:Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

| PRJNA596523 | ENA

Expression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days

Project description:breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo. We used microarrays to compare gene expression changes of MCF7 breast xenograft treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days Breast xenograft MCF7 bearing mice treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days. RNA were extracted from tumors and hybridizedon Affymetrix microarrays to compare gene expression changes

2011-11-02 | E-GEOD-33366 | biostudies-arrayexpress

Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole

Project description:Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole

| PRJNA272564 | ENA